Companies/Avivagen Inc.

Company profile

Avivagen Inc.

OTC: VIVXF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Ottawa, ONReports USD

#893 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 34

v0.1 · 5/100 weight · pillars only

↑ Piotroski F, listing tenure · ↓ Altman-Z, return on assets

Methodology →

Revenue TTM

$535.9k

Rev growth YoY (TTM)

-12.8%

Net income (FY)

-$4.7M

Employees

Market cap

$7.8k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$729.5k939.2k CAD2022

Net income-$4.7M-6.1M CAD2022

Operating income-$3.8M-4.9M CAD2022

Total assets$1.0M1.4M CAD2022

Liabilities$5.4M7.3M CAD2022

Equity-$4.4M-6.0M CAD2022

Revenue trend

FY2017 – FY2022 · USD

$196.3k

FY17

$833.3k

FY18

$735.7k

FY19

$875.2k

FY20

$1.0M

FY21

$729.5k

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Avivagen Inc. booked $729.5k in FY2022 revenue, contracting 29% year over year — slower than 76% of Healthcare companies we track, at a -645.9% net margin.

Peers · Healthcare

Alternate Health Corp.——Winston Pharmaceuticals, Inc.——Biostax Corp.——Arrayit Corporation——

Key facts

CEOG. F. Kym Anthony

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersOttawa, ON

ExchangeOTC: VIVXF

Employees13

IPO date2013-05-02

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.